Macugen
pegaptanib
Table of contents
Withdrawn
This medicine is now withdrawn from use in the European Union.
Overview
The marketing authorisation for Macugen has been withdrawn at the request of the marketing-authorisation holder.
This EPAR was last updated on 02/12/2022
Authorisation details
| Product details | |
|---|---|
| Name |
Macugen
|
| Agency product number |
EMEA/H/C/000620
|
| Active substance |
pegaptanib
|
| International non-proprietary name (INN) or common name |
pegaptanib
|
| Therapeutic area (MeSH) |
Wet Macular Degeneration
|
| Anatomical therapeutic chemical (ATC) code |
S01LA03
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
PharmaSwiss Ceska Republika s.r.o
|
| Revision |
15
|
| Date of issue of marketing authorisation valid throughout the European Union |
31/01/2006
|
| Contact address |
Jankovcova 1569/2c
Lighthouse 17000 Prague 7 Czech Republic |
Product information
20/07/2016 Macugen - EMEA/H/C/000620 - IB/0065
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Pharmacotherapeutic group
Ophthalmologicals
Therapeutic indication
Therapeutic indication
Macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).